2121 2nd Street
About Evolve BioSystemsEvolve Biosystems is a spin-out from the Foods For Health Institute (FFHI) at the University of California, Davis.
The company builds on more than a decade of research into the infant gut microbiome and its intimate interaction with breast milk components, established by the founding scientists including Bruce German, David Mills, Carlito Lebrilla, Daniela Barile and Samara Freeman. Their fundamental research and translational clinical trials have been enabled by more than $15 million in federal and private grants since 2004.
CEO: David Kyle
COO: Timothy Brown
Please click here for Evolve job opportunities.
20 articles with Evolve BioSystems
Evolve BioSystems, Inc. Announces the Use of Activated B. infantis EVC001 by International Consortium to Study the Prevention of Type 1 Diabetes in Children
Evolve BioSystems, Inc. today announces that its product, activated B. infantis EVC001, will be used in one of the largest international clinical studies on preventing type 1 diabetes (T1D) in genetically predisposed children.
Evolve BioSystems Announces Major Strategic Investment from Cargill and Manna Tree to Support Innovative Probiotic That Dramatically Improves Infant Gut Health
Evolve BioSystems announced today that it completed a substantial first close in a $55 million Series D round of funding, led by Cargill, the global food, agricultural, financial and industrial products company and Manna Tree, an investment firm committed to improving human health.
Evolve BioSystems, Inc. announces Dr. Minhthy Nguyen as Senior Vice President of Research & Development, further advancing its position as the leader in infant gut health
Evolve BioSystems announced today that Dr. Minhthy Nguyen , PhD, has joined the company as Senior Vice President, Research & Development. Dr. Nguyen joins the company in anticipation of the pending announcement of positive results from several large clinical studies, positioning the company for a material leap forward in the infan
Infant Fecal pH Revealed as a Critical Indicator of Infant Gut Health and Resistance against Gut Pathogen Invasion
Updated Infant Fecal pH Range Identifies Deficiency of Beneficial Bacteria in Infant Gut Microbiome
Evolve BioSystems, Inc. Announces Collaboration with Janssen to Study the Impact of B. infantis EVC001 in the Reduction of Atopic Dermatitis
Evolve BioSystems, Inc., a global leader dedicated to improving human health through the gut microbiome, today announced a collaboration with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to conduct a clinical study in children at risk for developing atopic dermatitis.
RB and Evolve BioSystems announce a partnership in the sale of Evivo®, Evolve BioSystems' infant probiotic.
Evolve BioSystems And The Regents Of The University Of California Jointly File Patent Infringement Complaint Against Abbott Laboratories Regarding Infant Probiotic
Evolve BioSystems and the Regents of the University of California have jointly filed and served a patent infringement complaint against Abbott Laboratories.
University of California, Davis Study Shows up to 98% Reduction of Intestinal Inflammation Markers Linked to Colic, Eczema, Asthma and Diabetes
Breakthrough Study Reveals Activated B. infantis EVC001 as the First Infant Probiotic to Be Effective in the Fight Against Global Health Epidemic
Evivo Stool Test Prototype Provides Clear Window into Infant Gut Health
Significant Reduction in Pathogenic Gut Bacteria Lowers Potential for Infection Risk in Infants Fed B. infantis EVC001
Evolve BioSystems Demonstrates 93 Percent Drop in Common Pathogens such as E. coli, C. difficile
Evolve BioSystems Announces $40 Million Series C Financing to Expand its Flagship Infant Probiotic Product Evivo
Bill & Melinda Gates Foundation, Li Ka Shing Foundation Lead New Funding Round to Expand Groundbreaking Progress in Restoring Infant Gut Microbiome and to Lay a Global Foundation for Long-Term Nutritional and Immune Health
Evolve BioSystems Partners With King’s College London to Resolve Gut Dysbiosis in C-Section Delivered Infants
The study will investigate the impact of dietary B. infantis EVC001, combined with breastfeeding, in restoring intestinal Bifidobacterium in infants delivered by Caesarean-section, a known cause of infant gut dysbiosis.
Evolve BioSystems' Activated B. infantis EVC001 Demonstrates Substantial and Persistent Remodeling of the Infant Gut Microbiome
The study showed that providing dietary B. infantis EVC001 resulted in rapid, substantial, and persistent remodeling of the gut microbiome in breastfed infants.
Evolve BioSystems' Evivo Gains Health Canada Approval, Providing First International Expansion Opportunity
The license, granted by Health Canada, states that Evivo is safe to give once a day to babies under 1 year of age.
Evolve BioSystems Announces Timothy B. Brown As New CEO, David Kyle Named Executive Chairman And Chief Scientific Officer
Evolve BioSystems Successfully Defends European Patent Opposition By Danone, Maintaining Their Position As Leaders In The Infant Gut Microbiome Space
Evolve BioSystems Names Pure Moxie Branding Agency Of Record In The Launch Of Its Breakthrough Microbiome Products